linjc16/ctgov huggingface dataset:
Effectiveness of DN Versus TU Along With Routine PT in Patients With for Chronic Neck Pain RCT

Study Overview
=================
Brief Summary
-----------------
To determine the effectiveness of dry needling and therapeutic ultrasound for the treatment of chronic neck pain

Official Title
-----------------
Effectiveness of Dry Needling Versus Therapeutic Ultrasound Along With Routine Physical Therapy in Patients With for Chronic Neck Pain; a Randomized Control Trial

Conditions
-----------------
Neck Pain

Intervention / Treatment
-----------------
* Diagnostic Test: Dry needling
* Diagnostic Test: Therapeutic ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The inclusion criteria will be office workers having pain sensation at neck for at least 4 months pain for 3-7 on NRS and with the limited or painful ROM. Age of the participants will be 20-35 years. Only those individuals will be included who are working in the field for more than 8 months and work for 6-8 hours per day. Exclusion Criteria: The exclusion criteria were any other neurological conditions of cervical vertebra, cervical radiculopathy, any vascular disease, tumors or any other local infection

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Dry needling<br> | Diagnostic Test: Dry needling<br>* Dry Needling Along With Routine Physical Therapy for Chronic Neck Pain<br>|
| Experimental: therapeutic ultrasound<br> | Diagnostic Test: Therapeutic ultrasound<br>* Therapeutic ultrasound Along With Routine Physical Therapy for Chronic Neck Pain<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Range of Motion Scale | Range of Motion is a measuring scale, specifically designed to allow patients and providers to measure the opening, movement and function of the mouth and jaw | 3 Months | 
| Visual Analog Scale for pain the lower score is better | Visual Analog Scale Ranges1-10 scaling normal to worst | 3 Months |
Investigation of the Relationship Between Development, Neurological Assessment and Object Permanence in High Risk Infants.

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to examine the relationship between development, neurological assessment and object permanence in risky infants aged 7-16 months. The sample of the study will consist of babies between 7-16 months at risk (preterm, low birth weight, asphyxia, hyperbillirubinemia, etc.). Inclusion criteria for the study: Between 7-16 months, having at least one risk factor. Exclusion criteria: Medical complications (eg, severe visual impairment) limiting participation in assessments; autism, down syndrome, or spinal cord injury; diagnosed uncontrolled seizure disorder; or a neurodegenerative disorder. Parents who agreed to participate in the study will be asked to fill out the demographic information questionnaire. Object permanence scale, Bayley III infant and toddler development scale and Hammersmith infant neurologic assessment will be applied to infants.

Official Title
-----------------
Investigation of the Relationship Between Development, Neurological Assessment and Object Permanence in High Risk Infants.

Conditions
-----------------
Infant Development

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 7-16 months, having at least one risk factor Exclusion Criteria: Medical complications (eg, severe visual impairment) limiting participation in assessments; autism, down syndrome, or spinal cord injury; diagnosed uncontrolled seizure disorder; or a neurodegenerative disorder

Ages Eligible for Study
-----------------
Minimum Age: 7 Months
Maximum Age: 16 Months

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Object Permanence Scale | The minimum score of the Object Permanence Scale is 0, and the maximum score is 10. Higher scores indicate better outcome. | Baseline | 
| The Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) motor and cognitive subscales | Cognitive subscale consists of 91 items and Motor subscale consists of 138 items. Items are scored as 1 (done) and 0 not able to). Higher scores indicate better outcome. | Baseline | 
| Hammersmith infant neurological assessment | Each item is individually scored from zero to three, and individual scores are summed to obtain a global optimality score. The overall score can range from a minimum of 0 to a maximum of 78 points. | Baseline |
Risk-adapted Strategy Including Magnetic Resonance Imaging and Prostate-specific Antigen Density in Blood for Biopsy Decision in Patients With Lesions Suspicious for Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
Recent guidelines now recommend multi parametric magnetic resonance imaging prior to biopsy for all men as an integral part of improved diagnosis of clinical significant prostate cancer. However, magnetic resonance imaging targeted biopsy is a strategy that focuses on maximizing detection of clinical significant prostate cancer, but this procedure has the disadvantage of leading to higher detection of clinically insignificant prostate cancers. One of the risk-stratifications developed to minimize the existing disadvantages and avoid unnecessary biopsy procedures is a strategy in which multi parametric magnetic resonance imaging and prostate-specific antigen density are used in combination. This is especially important in all patients with PI-RADS (Prostate Imaging Reporting and Data System) 3 lesions which are also interpreted as indeterminate mpMRI findings. Current guidelines suggest that biopsy may be omitted in some patient groups with PI-RADS 3 lesions in the risk-adapted strategy involving prostate-specific antigen density. The aim of this study was to evaluate the role of risk-adapted strategies involving prostate-specific antigen density in biopsy decision to avoid unnecessary biopsy vs the risk of missing clinical significant prostate cancer diagnosis in patients with PI-RADS 3 lesions.

Official Title
-----------------
Risk-adapted Strategy Combining Magnetic Resonance Imaging and Prostate-specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 'Gray Zone' Lesions

Conditions
-----------------
Prostate Cancer, Prostate Adenocarcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who all had undergone multi parametric magnetic resonance imaging at our hospital Patients who all had undergone transrectal ultrasonography guided cognitive and fusion targeted biopsies Exclusion Criteria: Magnetic resonance imaging at exterior hospitals Insufficient image quality/artifacts Previous prostate biopsy and/or prior prostate cancer diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reducing unnecessary prostate biopsy with the combined use of magnetic resonance imaging and prostat-specific antigen density measurement |  | 2 weeks from the outpatient clinic admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate cancer, Risk-adapted strategy, Magnetic resonance imaging, Prostate-specific antigen density, PIRADS
Influence of Combined Double-Bundle ACL Reconstruction With Lateral Retinacular Release to Prevent Patellofemoral Malalignment in Isolated ACL Rupture

Study Overview
=================
Brief Summary
-----------------
Anterior knee pain which might be due to patellofemoral malalignment is an inevitable post operative complication after an ACL reconstruction (ACLR). We combined the double bundle ACLR technique with lateral release technique to prevent patellofemoral malalignment post ACLR.

Official Title
-----------------
Influence of Combined Double-Bundle ACL Reconstruction With Lateral Retinacular Release to Prevent Patellofemoral Malalignment in Isolated ACL Rupture: a Randomized Controlled Trial

Conditions
-----------------
ACL Injury

Intervention / Treatment
-----------------
* Procedure: ACL reconstruction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: unilateral isolated total ACL rupture normal BMI Exclusion Criteria: flexion contracture more than 200, presence of anterior knee pain before surgery, Q angle >140 in males and >170 in females, presence of a patellar tilting, rupture of other ligaments, and muscular dysfunction.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group 1<br>Single bundle group | Procedure: ACL reconstruction<br>* performed arthroscopically<br>|
| Active Comparator: Group 2<br>Double bundle only group | Procedure: ACL reconstruction<br>* performed arthroscopically<br>|
| Experimental: Group 3<br>Double bundle with lateral release group | Procedure: ACL reconstruction<br>* performed arthroscopically<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TTTG value | tibial tuberosity to trochlea groove, radiographic outcome | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Kujala score | functional outcome | 6 months |
Comparison of I-FFQ and Two Reference Methods

Study Overview
=================
Brief Summary
-----------------
Mild-to-moderate iodine deficiency remains a problem in many parts of the world, including Norway. Of particular concern are fertile, pregnant, and lactating women. The Norwegian Dairy Council developed a digital iodine-specific food frequency questionnaire (I-FFQ) for the assessment of iodine intake levels, but it has yet to be validated. The main objective was thus to investigate the relative validity of the I-FFQ by comparing estimates of iodine intake obtained from the I-FFQ against a single 24-hour recall (24HR) and urinary iodine concentration (UIC) in fertile women.

Official Title
-----------------
Comparison of a Digital Iodine-specific Food Frequency Questionnaire With 24-hour Recall and Urinary Iodine Concentration

Conditions
-----------------
Iodine Deficiency

Intervention / Treatment
-----------------
* Biological: spot urine samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy women aged 18-40 years sufficient language skills to be able to complete the questionnaires in Norwegian be able to meet physically at the study center in Bergen Exclusion Criteria: being pregnant, lactating, or having known thyroid disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: spot urine samples|No intervention, but measurement of urinary iodine concentration by 6 repeated spot urine samples|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of FFQ with 24-hour recall | Comparison of estimated dietary iodine intake from food-frequency questionnaire (FFQ) with dietary iodine intake from 24-hour recall | One week | 
| Comparison of FFQ with urinary iodine concentration | Comparison of estimated iodine intake from food-frequency questionnaire (FFQ) with urinary iodine concentration (UIC) | One week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
validation, food frequency questionnaire
Insights Into Participating in Studies for Bone Cancer

Study Overview
=================
Brief Summary
-----------------
Clinical studies, with a distinct focus on bone cancer, play a crucial role in evaluating the safety and effectiveness of novel treatments for this disease. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.

Official Title
-----------------
Examining Patient Involvement Patterns and Trends in Participation in Bone Cancer Clinical Trials

Conditions
-----------------
Bone Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed Diagnosis of bone cancer No prior treatment for bone cancer Exclusion Criteria: Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial Enrolled in another research study Inability to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a bone cancer clinical research. |  | 3 months | 
| Number of bone cancer study participants who remain in clinical study until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bone Cancer
The Relationship of Serum Uric Acid With Severity of Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
Osteoarthritis (OA) is the most prevalent form of arthritis. Its pathogenesis remains poorly understood. Though historically regarded as a disease of mechanical degeneration, it is now appreciated that inflammation plays an important role in OA pathogenesis (Krasnokutsky et al., 2017). The hallmark of OA is the degradation and loss of articular cartilage, although most tissues of the joint become affected, such as bone, synovium, ligaments, menisci (knee), labrum (hip), periarticular fat, and muscle (Englund, 2023).It is believed that there is a pathological link between hyperuricemia and OA Therefore, we conducted a cross-sectional study to evaluate an association between elevated SUA and radiographic OA of the knee) Bipan Shrestha, 2019 (.

Official Title
-----------------
The Relationship of Serum Uric Acid With Severity of Knee Osteoarthritis

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Diagnostic Test: serum uric acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient (Age>18 years) with a complaint of knee pain. Exclusion Criteria: 1.Any patient with a history of trauma to the knee. 2 Any patient with knee complaints as a part of autoimmune connective tissue disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cases group<br>hyperurecemic | Diagnostic Test: serum uric acid<br>* to detect the relaton ship of serum uric acid with sevwrity of knee osteoarthritis<br>|
| control group<br>normal | Diagnostic Test: serum uric acid<br>* to detect the relaton ship of serum uric acid with sevwrity of knee osteoarthritis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of serum uric acid | detect the relationship of serum uric acid with severity of knee osteoarthritis | 6 months |
Role of Surgery in Management of Pineal Region Tumors in Children

Study Overview
=================
Brief Summary
-----------------
The aim of this observational study is to learn about the role of surgery with its different approaches and modalities in the management of pineal region tumors in pediatric population.the main question it aims to answer is : How can surgery affect the outcome in children with pineal region tumors ?

Official Title
-----------------
Role of Surgery in Management of Pineal Region Tumors in Children

Conditions
-----------------
Brain Tumor

Intervention / Treatment
-----------------
* Procedure: Microsugical Excsosion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with pineal region tumors with age less than or equal to 18 years old and fit for surgical intervention Exclusion Criteria: patients with pineal region tumors older than 18 years old and pediatric patients younger than 18 years ild and unfit for surgical intervention

Ages Eligible for Study
-----------------
Minimum Age: 2 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Microsugical Excsosion|Microsurgical excision of pineal region tumor or endoscopic biopsy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| role of surgery and its effect in improving quality of life in children with pineal region tumors | evaluation of effect of surgical management with its different approaches in improvement of quality of life and performance status using Karnofsky Performance score (KPS) and radiological imaging till referral to adjuvant therapy | three years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pineal region
ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study

Study Overview
=================
Brief Summary
-----------------
The ITHACA study is a phase I study evaluating the safety and toxicity of a peritumorally injected PD-1 checkpoint inhibitor, in combination with a multifunctional CTLA-4 inhibitor, in early-stage cervical cancer.

Detailed Description
-----------------
In this single arm, open label phase I study, the investigators will study the safety and toxicity of the combination of a PD-1 checkpoint inhibitor and a multifunctional CTLA-4 inhibitor when injected peritumorally prior to surgery in early-stage cervical cancer. Additional objectives are to describe dose limiting toxicities, to determine the maximum tolerated doses and to study the effects on the tumor and lymph node microenvironment, and on immune subsets in peripheral blood.

Official Title
-----------------
ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study: Safety, Toxicity and Immunological Effects of Peritumorally Delivered Immunotherapy in Early-stage Cervical Cancer

Conditions
-----------------
Cervical Cancer

Intervention / Treatment
-----------------
* Drug: Anti-PD-1 antibody balstilimab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: early-stage cervical cancer scheduled for (radical) hysterectomy and pelvic lymph node dissection Exclusion Criteria: previous treatment with checkpoint inhibitors use of immunosuppressive medication within 28 days of the injection of the study medication history of other malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PD-1 checkpoint inhibitor and CTLA-4 inhibitor<br>Both antibodies will be peritumorally administered in early-stage cervical cancer prior to surgery. | Drug: Anti-PD-1 antibody balstilimab<br>* Both antibodies will be neoadjuvantly administered around the cervical tumor.<br>* Other names: Anti-CTLA-4 antibody botensilimab;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose limiting toxicity | Type and severity of side effects according to CTCAE v 5.0. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum tolerated dose | The highest dose administered without unacceptable toxicity | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immune therapy, Check point inhibitor, Peritumoral administration